inHEART

Executive Summary

inHEART is a French medical technology company that has developed an AI-powered digital twin platform for cardiac ablation procedures. Founded in 2017 and headquartered in Bordeaux, the company's proprietary software analyzes CT and MR scans to generate detailed 3D models of a patient's heart, enabling electrophysiologists to precisely plan and execute treatments for ventricular tachycardia (VT) and other arrhythmias. By providing a comprehensive anatomical map, inHEART aims to improve procedural efficiency, reduce complications, and enhance clinical outcomes in cardiac electrophysiology. The platform leverages advanced machine learning algorithms to automate segmentation and modeling, potentially reducing planning time from hours to minutes. With a focus on image-guided interventions, inHEART addresses a critical need in the growing market for structural heart disease therapies, where precision and personalization are increasingly valued. The global cardiac ablation market is projected to exceed $10 billion by 2030, driven by rising prevalence of arrhythmias and technological advancements. inHEART's digital twin differentiates by offering pre-procedural planning that can be integrated with existing mapping systems, thus fitting seamlessly into clinical workflows. The company has the potential to capture significant market share if it secures regulatory clearances and establishes partnerships with key players in the electrophysiology space. With its strong IP portfolio and clinical collaborations, inHEART is well-positioned to become a standard tool for complex ablation cases. Near-term catalysts include FDA clearance, clinical data publications, and strategic alliances.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for VT ablation planning software70% success
• Q2 2026Publication of pivotal study results at HRS 202680% success
• H2 2026Strategic partnership with a major cardiac mapping company50% success